Aclidinium/Formoterol

ApprovedSmall molecule

Aclidinium/Formoterol is one of 56 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Physical ActivityActive, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Physical ActivityApproved

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Aclidinium/Formoterol

AstraZeneca

Approved

1 2

Flovent

GSK

Preclinical

6 3

Spiriva

Boehringer Ingelheim

Preclinical

15 4

Aclidinium Bromide

AstraZeneca

Preclinical

21 5

Formoterol Fumarate

AstraZeneca

Preclinical

11 6

Atrovent

Boehringer Ingelheim

Preclinical

5 7

Calciferol

Alnylam Pharmaceuticals

Preclinical

—8

Proventil

Mylan Pharmaceuticals Inc

Preclinical

3 9

Narcan

SScienture

Preclinical

1 10

Zoloft

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01551888·24 enrolled

Physical Activity1 trial

Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT02424344·267 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Aclidinium/Formoterol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aclidinium/Formoterol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aclidinium/Formoterol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Aclidinium/Formoterol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Physical Activity1 trial

References

Drug Info

Quick Facts

Related News